SIRT2 plays a key role in both cell cycle regulation and cell survival of BV2 microglia

International Journal of Physiology, Pathophysiology and Pharmacology

Volumn 6, Issue 3, 2014, Pages 166-171

  Nie, Hui ^a   Li, Yexin ^a,d   Wang, Caixia ^a   Chen, Xuehua ^b   Liu, Bingya ^b   Wu, Danhong ^c   Ying, Weihai ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d Microbiology Institute of Shanxi   (China)

Author keywords

Apoptosis; Cell cycle; Microglia; Neurological disorders; SIRT2

Indexed keywords

7 AMINODACTINOMYCIN; LACTATE DEHYDROGENASE; LIPOCORTIN 5; SIRTUIN 2; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL SURVIVAL; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; MICROGLIA; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84907987621     PISSN: None     EISSN: 19448171     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999; 260: 273-279.
2. Nakagawa T and Guarente L. Sirtuins at a glance. J Cell Sci 2011; 124: 833-838.
3. Feldman JL, Dittenhafer-Reed KE and Denu JM. Sirtuin catalysis and regulation. J Biol Chem 2012; 287: 42419-42427.
4. Houtkooper RH, Pirinen E and Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 2012; 13: 225-238.
5. Finkel T, Deng CX and Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-591.
6. Narayan N, Lee IH, Borenstein R, Sun J, Wong R, Tong G, Fergusson MM, Liu J, Rovira II, Cheng HL, Wang G, Gucek M, Lombard D, Alt FW, Sack MN, Murphy E, Cao L and Finkel T. The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature 2012; 492: 199-204.
7. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC and McLean PJ. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson’s disease. Science 2007; 317: 516-519.
8. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H and Gokce O. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Nati Acad Sci U S A 2010; 107: 7927-7932.
9. He X, Nie H, Hong Y, Sheng C, Xia W and Ying W. SIRT2 activity is required for the survival of C6 glioma cells. Biochem Biophys Res Commun 2012; 417: 468-472.
10. Li Y, Matsumori H, Nakayama Y, Osaki M, Kojima H, Kurimasa A, Ito H, Mori S, Katoh M and Oshimura M. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells 2011; 16: 34-45.
11. Dryden SC, Nahhas FA, Nowak JE, Goustin AS and Tainsky MA. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol 2003; 23: 3173-3185.
12. Bae NS, Swanson MJ, Vassilev A and Howard BH. Human histone deacetylase SIRT2 interacts with the homeobox transcription factor HOXA10. J Biochem 2004; 135: 695-700.
13. Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, Nakano S, Katoh M, Ito H and Oshimura M. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 2007; 26: 945-957.
14. Pandithage R, Lilischkis R, Harting K, Wolf A, Jedamzik B, Lüscher-Firzlaff J, Vervoorts J, Lasonder E, Kremmer E and Knöll B. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell biol 2008; 180: 915-929.
15. Perry VH, Nicoll JAR and Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol 2010; 6: 193-201.
16. Nimmerjahn A, Kirchhoff F and Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308: 1314-1318.
17. Wang Q, Tang XN and Yenari MA. The inflammatory response in stroke. J Neuroimmunol 2007; 184: 53-68.
18. Gomes-Leal W. Microglial physiopathology: how to explain the dual role of microglia after acute neural disorders? Brain Behav 2012; 2: 345-356.
19. Pais TF, Szego EM, Marques O, Miller-Fleming L, Antas P, Guerreiro P, de Oliveira RM, Kasapoglu B and Outeiro TF. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation. EMBO J 2013; 32: 2603-16.
20. Feng R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B and Zhu Z. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 2010; 298: 50-63.
21. Alano CC, Ying W and Swanson RA. Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J Biol Chem 2004; 279: 18895-18902.
22. Li Y, Nie H, Wu D, Zhang J, Wei X and Ying W. Poly(ADP-ribose) polymerase mediates both cell death and ATP decreases in SIRT2 inhibitor AGK2-treated microglial BV2 cells. Neurosci Lett 2013; 544: 36-40.